PRMT1 regulates tumor growth and metastasis of human melanoma via targeting ALCAM

Li,Lei; Zhang,Zhengwen; Ma,Tengxiao; Huo,Ran

doi:10.3892/mmr.2016.5273

PRMT1 regulates tumor growth and metastasis of human melanoma via targeting ALCAM

Authors:
- Lei Li
- Zhengwen Zhang
- Tengxiao Ma
- Ran Huo
View Affiliations

Affiliations: Department of Aesthetic Plastic and Burn Surgery, Shandong Provincial Hospital, Shandong University, Jinan, Shandong 250000, P.R. China, Department of Plastic and Reconstructive Surgery, Henan Provincial People's Hospital, Zhengzhou, Henan 450000, P.R. China
Published online on: May 13, 2016 https://doi.org/10.3892/mmr.2016.5273
Pages: 521-528

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Overexpression of protein arginine methyltransferases (PRMTs) is associated with various types of cancer. The present study aimed to determine the expression level of PRMT1 in human melanoma and investigate its biological function. The clinical significance of PRMT1 was determined by screening the Oncomine database, and the increased expression of PRMT in melanoma was confirmed by western blot analysis. Furthermore, the current study demonstrated that PRMT1 was overexpressed in melanoma cell lines compared with human immortalized keratinocytes and PIG1 immortalized human melanocytes. Silencing PRMT1 in A375 and Hs294T cells significantly suppressed tumor growth and metastatic ability of the melanoma cell line compared with the negative control. These changes were in accordance with the upregulation of the cadherin 1 level and downregulation of several metastatic‑associated genes determined by a quantitative polymerase chain reaction array. Liquid chromatography‑mass spectrometry demonstrated that activated leukocyte cell adhesion molecule (ALCAM) may be a direct target of PRMT1, and the interaction was confirmed by co‑immunoprecipitation. Compared with negative controls, the protein level of ALCAM was decreased following the silencing of PRMT1, and re‑expression of ALCAM in A375/shPRMT1 or Hs294T/shPRMT1 cells using an expression vector restored the colony formation and metastatic ability of the cells. In conclusion, the current results indicated that PRMT1 is overexpressed in human melanoma, and may regulate tumor growth and metastasis via targeting ALCAM.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	Itakura E, Huang RR, Wen DR, Paul E, Wünsch PH and Cochran AJ: IL-10 expression by primary tumor cells correlates with melanoma progression from radial to vertical growth phase and development of metastatic competence. Mod Pathol. 24:801–809. 2011. View Article : Google Scholar : PubMed/NCBI
3	Gandini S, Sera F, Cattaruzza MS, Pasquini P, Picconi O, Boyle P and Melchi CF: Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer. 41:45–60. 2005. View Article : Google Scholar
4	Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, et al: Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 4:80–93. 2014. View Article : Google Scholar :
5	Puig-Butille JA, Escámez MJ, Garcia-Garcia F, Tell-Marti G, Fabra À, Martínez-Santamaría L, Badenas C, Aguilera P, Pevida M, Dopazo J, et al: Capturing the biological impact of CDKN2A and MC1R genes as an early predisposing event in melanoma and non melanoma skin cancer. Oncotarget. 5:1439–1451. 2014. View Article : Google Scholar : PubMed/NCBI
6	Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Spatz A, Grob JJ, Malvehy J, Newton-Bishop J, Stratigos A, et al: Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer. 46:270–283. 2010. View Article : Google Scholar
7	Loquai C, Schmidtmann I, Beutel M, Sunderkötter C, Grabbe S, Schiller M and Nashan D: Quality of life in melanoma patients during adjuvant treatment with pegylated interferon-α2b: Patients' and doctors' views. Eur J Dermatol. 21:976–984. 2011.PubMed/NCBI
8	Dillman RO, DePriest C, Ellis R and de Leon C: 5-year survival for patients with metastatic melanoma who had no evidence of disease at time of treatment with patient specific tumor stem cell vaccines. Cancer Research. 74:1972014. View Article : Google Scholar
9	Di Lorenzo A and Bedford MT: Histone arginine methylation. FEBS Lett. 585:2024–2031. 2011. View Article : Google Scholar
10	Wysocka J, Allis CD and Coonrod S: Histone arginine methylation and its dynamic regulation. Front Biosci. 11:344–355. 2006. View Article : Google Scholar
11	Yang Y and Bedford MT: Protein arginine methyltransferases and cancer. Nat Rev Cancer. 13:37–50. 2013. View Article : Google Scholar
12	Gu Z, Gao S, Zhang F and Wang Z, Ma W, Davis RE and Wang Z: Protein arginine methyltransferase 5 is essential for growth of lung cancer cells. Biochem J. 446:235–241. 2012. View Article : Google Scholar : PubMed/NCBI
13	Yoshimoto T, Boehm M, Olive M, Crook MF, San H, Langenickel T and Nabel EG: The arginine methyltransferase PRMT2 binds RB and regulates E2F function. Exp Cell Res. 312:2040–2053. 2006. View Article : Google Scholar : PubMed/NCBI
14	Qi C, Chang J, Zhu Y, Yeldandi AV, Rao SM and Zhu YJ: Identification of protein arginine methyltransferase 2 as a coactivator for estrogen receptor alpha. J Biol Chem. 277:28624–28630. 2002. View Article : Google Scholar : PubMed/NCBI
15	Nicholas C, Yang J, Peters SB, Bill MA, Baiocchi RA, Yan F, Sïf S, Tae S, Gaudio E, Wu X, et al: PRMT5 is upregulated in malignant and metastatic melanoma and regulates expression of MITF and p27 (Kip1). PLoS One. 8:e747102013. View Article : Google Scholar
16	Nicholas C, Yan F, Peters SB, Bill MA, Li P, Li C, Fuchs JR, Baiocchi R and Lesinski GB: The expression of PRMT5 methyltransferase mediates cell survival and metastatic phenotype in malignant melanoma. Cancer Research. 71:9332011. View Article : Google Scholar
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar
18	Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C, et al: A landscape of driver mutations in melanoma. Cell. 150:251–263. 2012. View Article : Google Scholar : PubMed/NCBI
19	Shayan R, Karnezis T, Murali R, Wilmott JS, Ashton MW, Taylor GI, Thompson JF, Hersey P, Achen MG, Scolyer RA and Stacker SA: Lymphatic vessel density in primary melanomas predicts sentinel lymph node status and risk of metastasis. Histopathology. 61:702–710. 2012.PubMed/NCBI
20	Shields CL, Kaliki S, Furuta M, Fulco E, Alarcon C and Shields JA: American Joint Committee on Cancer classification of posterior uveal melanoma (tumor size category) predicts prognosis in 7731 patients. Ophthalmology. 120:2066–2071. 2013. View Article : Google Scholar : PubMed/NCBI
21	Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 364:2507–2516. 2011. View Article : Google Scholar : PubMed/NCBI
22	Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L and Garraway LA: Highly recurrent TERT promoter mutations in human melanoma. Science. 339:957–959. 2013. View Article : Google Scholar : PubMed/NCBI
23	Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker JP, Cheng E, Davis MJ, Goh G, Choi M, et al: Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet. 44:1006–1014. 2012. View Article : Google Scholar : PubMed/NCBI
24	Bao X, Zhao S, Liu T, Liu Y, Liu Y and Yang X: Overexpression of PRMT5 promotes tumor cell growth and is associated with poor disease prognosis in epithelial ovarian cancer. J Histochem Cytochem. 61:206–217. 2013. View Article : Google Scholar : PubMed/NCBI
25	Weichert W, Knösel T, Bellach J, Dietel M and Kristiansen G: ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival. J Clin Pathol. 57:1160–1164. 2004. View Article : Google Scholar : PubMed/NCBI
26	Verma A, Shukla NK, Deo SV, Gupta SD and Ralhan R: MEMD/ALCAM: A potential marker for tumor invasion and nodal metastasis in esophageal squamous cell carcinoma. Oncology. 68:462–470. 2005. View Article : Google Scholar : PubMed/NCBI
27	Degen WG, Van Kempen LC, Gijzen EG, van Groningen JJ, van Kooyk Y, Bloemers HP and Swart GW: MEMD, a new cell adhesion molecule in metastasizing human melanoma cell lines, is identical to ALCAM (activated leukocyte cell adhesion molecule). Am J Pathol. 152:805–813. 1998.PubMed/NCBI
28	Swart GW, Lunter PC, Kilsdonk JW and Kempen LC: Activated leukocyte cell adhesion molecule (ALCAM/CD166): Signaling at the divide of melanoma cell clustering and cell migration? Cancer Metastasis Rev. 24:223–236. 2005. View Article : Google Scholar : PubMed/NCBI
29	Lunter PC, Van Kilsdonk JW, Van Beek H, Cornelissen IM, Bergers M, Willems PH, van Muijen GN and Swart GW: Activated leukocyte cell adhesion molecule (ALCAM/CD166/MEMD), a novel actor in invasive growth, controls matrix metalloproteinase activity. Cancer Res. 65:8801–8808. 2005. View Article : Google Scholar : PubMed/NCBI